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Introduction
Fractures are associated with increased morbidity and mortality, and place a considerable economic burden upon health care systems [2] . Patients with type 2 diabetes (T2D) are at increased fracture risk, both from the disease itself and potentially from associated medications [3] . Since 2007, incretin agents, such as dipeptidyl peptidase 4-inhibitors (DPP4-Is) and glucagon-like peptide 1 receptor agonists (GLP1-ras), have been available for the treatment of T2D. Interestingly, a meta-analysis, solely based upon randomized controlled trial (RCT) data, showed that the use of DPP4-Is was associated with a 40% reduction in fracture risk [4] . In contrast, metaanalyses showed that GLP1-ra use was not associated with fracture risk [5, 6] , although stratification by type of GLP1-ra resulted in a 62% risk with a specific GLP1-ra, while another type showed a two-fold increased risk [6] . We have recently investigated the association between incretin use and fracture risk, using real-life data from large population-based cohorts [7] [8] [9] [10] . In contrast to the RCT meta-analyses [4, 6] we did not observe a reduced fracture risk with use of either incretin.
The aim of the present study was to obtain the highest quality estimate of the effect of incretins on fracture risk in the real-world situation by meta-analysis of the available population-based cohort data.
Methods
Extensive supplemental information on the methods (search strategy and statistical analysis) is electronically available. In brief, we searched for studies investigating either DPP4-I or GLP1-ra agents and fracture risk up to 2015. To be included, a study had to meet the following criteria: use of an observational study design; compare the use of at least one of the incretin agents (DPP4-I or GLP1-ra) to the use of other oral glucose-lowering drugs; report fractures as outcome variable; report relative risks (RR), odds ratios or hazard ratios including 95% confidence intervals (CIs); the studies had to be written in English. Adjusted results were pooled using generic inverse variance methods, assuming a random effects model. Analyses were performed using RevMan Version 5.3 (Cochrane Collaboration, Oxford, UK).
Results
In total, four studies were included in the present meta-analysis and they contained 22 961 current DPP4-I users (568 fractures) and 8505 current GLP1-ra users (202 fractures) [7] [8] [9] [10] (supplemental Table S1 , Figure S1 ).
We found that neither current DPP4-I use, nor current GLP1-ra use was associated with a decreased risk of fracture (corresponding forest plots Figures Table S2 ).
Discussion
The results of this meta-analysis on real-life population-based data demonstrate that, contrary to pooled RCT-data [4, 6] , the current use of incretins (either DPP4-Is or GLP1-ras) was not associated with a decreased fracture risk. Moreover, GLP1-ra use was associated with an increased risk of any fracture if the average daily dosage exceeded 22.5 μg day -1 . The present results were in line with a previous meta-analysis, showing no association between use of GLP1-ra and risk of fracture [5] . It is possible that the discrepancies between the pooled RCTdata and our real-life population-based data may be a result of selection bias due to the use of strict inclusion and exclusion criteria with RCTs and the fact that data on fractures in the RCT studies were not predefined outcomes and therefore not routinely systematically collected. Importantly, the notion that incretins may have skeletal effects stems from in vitro and experimental animal studies, possibly acting via osteoclast inhibition and modulation of thyroid C-cells, which express incretin receptors [11, 12] ; the translation of such observations to the human clinical situation must be viewed with caution. A particular strength of this short report is, next to its analyses of real-life population-based data, its use of the same cumulative and average daily dose categories which allowed us to use the same definitions across the studies. The number of fractures with current GLP1-ra use was relatively small, which limited the statistical power to detect associations, particularly when stratified by cumulative exposure, average daily dose and fracture type. In addition, only a small number of observational studies, all performed by us, could be included in the present meta-analysis. Another limitation is the relative short duration of incretin use (37 weeks to 1.7 years) [7] [8] [9] [10] . We nevertheless have tested the hypothesis that incretin use was associated with a decreased risk of fracture in multiple ways, and none of the analyses showed a decreased risk of fracture. Moreover, we used data representative for the UK (2007 UK ( -2012 and data on all fractures in Denmark between 2007 and 2011.
In short, this meta-analysis demonstrated that the current use of incretin agents, either DPP4-I or GLP1-ra, was not associated with decreased fracture risk. Moreover, current GLP1-ra use was associated with an increased risk of any fracture when the average daily dosage exceeded 22.5 μg day -1 . Our findings show the value of representative real-world populations, and the risks associated with suggesting benefits for medications on the basis of safety reporting in RCTs. An adequately powered trial with fracture as the primary endpoint will be required to properly demonstrate the skeletal efficacy or otherwise of incretins. 
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